Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study for Safety, Efficacy and Cellular Pharmacokinetics of CD7 CAR-T Cell for Patients With Relapsed or Refractory CD7 Positive T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

NCT05716113 is registered in ClinicalTrials.gov with He Huang as lead sponsor.

NCT NCT05716113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05716113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study for Safety, Efficacy and Cellular Pharmacokinetics of CD7 CAR-T Cell for Patients With Relapsed or Refractory CD7 Positive T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Lead sponsor
He Huang
Phase
Phase 1
Overall status
Completed
Start date
February 9, 2023
Completion date
August 31, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic diseases, hematologic neoplasms, neoplasms, neoplasms by site